Department of Clinical Laboratory, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.
Department of Clinical Laboratory, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
J Med Virol. 2022 Aug;94(8):3548-3553. doi: 10.1002/jmv.27798. Epub 2022 Apr 30.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection is the gold standard for the laboratory diagnosis of coronavirus disease 2019 (COVID-19). However, this method has high requirements for practitioners' skills and testing sites, so it is not easy to popularize and promote the application in places other than large hospitals. In addition, the detection flux of SARS-CoV-2 nucleic acid is small, and the whole detection process takes much time, which cannot meet the actual needs of rapid screening in large quantities. The WHO conditionally approved a batch of SARS-CoV-2 antigen reagents for clinical application to alleviate this contradiction. SARS-CoV-2 antigen detection offers a trade-off among clinical performance, speed and accessibility. With the gradual increase in clinical application, the accumulated clinical data show that the sensitivity and specificity of the SARS-CoV-2 antigen assay are over 80% and 97%, respectively, which can basically meet the requirements of the WHO. However, the sensitivity of the SARS-CoV-2 Antigen Assay among asymptomatic people in low prevalence areas of COVID-19 cannot meet the standard, leading to a large number of missed diagnoses. In addition, the detection ability of SARS-CoV-2 antigen reagent for different SARS-CoV-2 mutant strains differs greatly, especially for those escaping the COVID-19 vaccines. In terms of results interpretation, it is highly reliable to exclude SARS-CoV-2 infection based on the high negative predictive value of the SARS-CoV-2 antigen assay. However, in the low prevalence environment, the probability of false positives of the SARS-CoV-2 antigen assay is high, so the positive results need to be confirmed by the SARS-CoV-2 nucleic acid reagent. The SARS-CoV-2 antigen assay is only a supplement to SARS-CoV-2 nucleic acid detection and can never completely replace it. To date, SARS-CoV-2 nucleic acid detection continues to be the standard laboratory method for COVID-19 diagnosis.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)核酸检测是 2019 冠状病毒病(COVID-19)实验室诊断的金标准。然而,这种方法对检测人员的技术和检测场地要求较高,因此不易在除大医院以外的地方推广和应用。此外,SARS-CoV-2 核酸的检测通量较小,整个检测过程需要很长时间,无法满足大量快速筛查的实际需求。世界卫生组织(WHO)有条件批准了一批 SARS-CoV-2 抗原试剂用于临床应用,以缓解这一矛盾。SARS-CoV-2 抗原检测在临床性能、速度和可及性方面存在权衡。随着临床应用的逐步增加,积累的临床数据表明,SARS-CoV-2 抗原检测的灵敏度和特异性分别超过 80%和 97%,基本可以满足 WHO 的要求。然而,SARS-CoV-2 抗原检测在 COVID-19 低流行地区无症状人群中的灵敏度不能满足标准,导致大量漏诊。此外,SARS-CoV-2 抗原试剂对不同 SARS-CoV-2 突变株的检测能力差异很大,尤其是对逃避 COVID-19 疫苗的突变株。在结果解释方面,基于 SARS-CoV-2 抗原检测的高阴性预测值,可以高度可靠地排除 SARS-CoV-2 感染。然而,在低流行环境下,SARS-CoV-2 抗原检测的假阳性概率较高,因此需要用 SARS-CoV-2 核酸试剂对阳性结果进行确认。SARS-CoV-2 抗原检测只是 SARS-CoV-2 核酸检测的补充,永远不能完全替代它。迄今为止,SARS-CoV-2 核酸检测仍然是 COVID-19 诊断的标准实验室方法。